Previous 10 | Next 10 |
Zynex press release ( NASDAQ: ZYXI ): Q2 GAAP EPS of $0.08 beats by $0.01 . Revenue of $36.76M (+18.6% Y/Y) beats by $0.46M . Zynex is reaffirming its full year 2022 revenue estimates in the range of $150-$170 million and Adjusted EBITDA between $25-$35 million...
Zynex Announces 2022 Second Quarter Earnings PR Newswire ENGLEWOOD, Colo. , July 28, 2022 /PRNewswire/ -- Zynex, Inc . (NASDAQ: ZYXI) an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pa...
Zynex ( NASDAQ: ZYXI ) is scheduled to announce Q2 earnings results on Thursday, July 28th, after market close. The consensus EPS Estimate is $0.07 and the consensus Revenue Estimate is $36.3M (+17.1% Y/Y). Over the last 3 months, EPS estimates have seen 0 upward rev...
AAPL , AEMD , AJG , ALEX , AMZN , APPF , ATR , AUY , AVTR , AXTI , BIO , OTCPK:BTEGF , BZH , CC , CE , CLFD , CLR , COHU , CPT , CTO , CUZ , CWST , DECK , DLR , DXCM , EB , EBC , ...
Zynex continues to grow its top-line sequentially, set to post another record quarter in Q2. Despite this, investors have punished the stock in FY22, in search of idiosyncratic risk premia over beta-related return. In that vein, we find a lack of equity premia in ZYXI that investo...
Zynex, Inc. to Announce Second Quarter 2022 Financial Results PR Newswire ENGLEWOOD, Colo. , July 20, 2022 /PRNewswire/ -- Zynex, Inc . (NASDAQ: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medic...
Zynex ( NASDAQ: ZYXI ) reports that Q2 orders grew 19% Q/Q and 10% Y/Y, over Q2 2021, hitting the highest order total in Company history. Cash collections also remained strong during Q2. The company re-affirms Q2 revenue guidance of $35M-$38M ( $36.55M consensus ), up ...
Zynex Reports Preliminary Second Quarter 2022 Results and Reiterates Full Year Revenue and EBITDA Guidance PR Newswire ENGLEWOOD, Colo. , July 11, 2022 /PRNewswire/ -- Zynex, Inc . (NASDAQ: ZYXI), an innovative medical technology company specializing in t...
Gainers: Ocean Bio-Chem OBCI +117%. Exela Technologies XELA +47%. Boxed BOXD +44%. Revlon REV +39%. Vivakor (VIVK) +22%. Omeros Corporation (OMER) +21%. Vor Biopharma (VOR) +21%. Wave Life Sciences WVE +18%. Siyata Mobile (SYTA) +18%. Visionary Education Technology (V...
Zynex Announces Change of Auditor PR Newswire ENGLEWOOD, Colo. , June 13, 2022 /PRNewswire/ -- Zynex, Inc . ("Zynex or the "Company) (NASDAQ: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medi...
News, Short Squeeze, Breakout and More Instantly...
2024-07-26 16:37:00 ET Shares of pain-management equipment specialist Zynex (NASDAQ: ZYXI) were falling in Friday trading, down as much as 23.4%, before recovering to a 13.4% decline as of 3:25 p.m. EDT. The medical equipment company reported earnings last night that, on a headl...
A look at the top 10 most actives in the United States Selina Hospitality PLC (SLNA) rose 22.6% to $0.0461 on volume of 144,150,002 shares Vintage Wine Estates Inc. (VWE) rose 21.5% to $0.0849 on volume of 35,620,484 shares NVIDIA Corporation (NVDA) rose 2.4% to $115.03 on volume of 35,381,...
Zynex Reports Second Quarter 2024 Financial Results PR Newswire Q2 2024 Revenue Increased 11% to $49.9 Million ENGLEWOOD, Colo. , July 25, 2024 /PRNewswire/ -- Zynex, Inc. (NASDAQ: ZYXI), an innovative medical technology company specializing in the ma...